Posted by Michael Wonder on 06 May 2020
FDA approves first targeted therapy to treat aggressive form of lung cancer
6 May 2020 - Today, the U.S. FDA approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer that has spread to other parts of the body.
Tabrecta is the first FDA-approved therapy to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta today. Most patients had tumour samples that were tested for mutations that lead to MET exon 14 skipping using local tests and confirmed with the F1CDx, which is a next-generation sequencing based in vitro diagnostic device that is capable of detecting several mutations, including mutations that lead to MET exon 14 skipping.
